Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.

ABSTRACT:

Background

Antiretroviral therapy (ART) for HIV-1 treatment has improved lifespan but requires lifelong adherence for people living with HIV (PLWH), highlighting the need for a cure. Evaluation of potential cure strategies requires analytic treatment interruption (ATI) with close monitoring of viral rebound. Predictive biomarkers for HIV-1 rebound and/or duration of control during ATI will facilitate these HIV cure trials while minimizing risks. Available evidence suggests that host immune, glycomic, lipid, and metabolic markers of inflammation may be associated with HIV-1 persistence in PLWH who are treated during chronic HIV-1 infection.

Methods

We conducted post-hoc analysis of HIV controllers who could maintain low levels of plasma HIV-1 without ART in a phase 1b

SUBMITTER: Abdel-Mohsen M 

PROVIDER: S-EPMC11229794 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature